glp-1 medications for obesity What is the pipeline future for obesity? Medicare begins coverage of GLP-1

For most healthy adults on maintenance, once or twice a month is plenty

Recently, a real-world study showing association between incretin-based therapy and changes in taste perception with GLP-1 or dual GLP-1/GIP-RAs usage for around 40 weeks reported that independently to weight loss, there was an increase in sweet perception intensity up to 4.7 times and salt perception up to 3.2 times in around 20% of the participants, resulting as well in earlier satiety, and reduction of hunger and craving due to a major sensibilization to both flavors with any of these medication, although they did not mention further impact in weight loss or BMI change (170)

Mecasermin is the only FDA-approved IGF-1 product in the column

Comparative analyses of GLP-1RAs with other glucose-lowering agents reveal distinct safety profiles, emphasizing the critical importance of patient-specific treatment strategies